Could vaccines beat back Omicron? South African study offers first clues


56e0ce05-7481-4f99-a06e-ab460db8f836_6215caeb

South African researchers have provided the first tentative answers to the question of how well vaccines currently in use may protect against Omicron, the new and highly mutated coronavirus variant.

Their findings, made public on Tuesday ahead of peer review, indicated the variant was significantly better at evading virus-fighting antibodies produced by the Pfizer/BioNTech vaccine than previous strains. However, evasion was not complete and boosters could help increase protection, the findings suggested.

The results are the first set of what is expected to be a deluge of data on the subject in the coming days. Scientists have cautioned about the need for more research, real world data and corroboration, with an early study from Sweden already showing less stark reductions in protection in previously infected people.

Do you have questions about the biggest topics and trends from around the world? Get the answers with SCMP Knowledge, our new platform of curated content with explainers, FAQs, analyses and infographics brought to you by our award-winning team.

The Durban-based South African research team led by virologist Alex Sigal found people who had received two doses of the Pfizer/BioNTech mRNA shot experienced a 40-fold reduction in levels of neutralising antibodies against Omicron, compared to those against an earlier strain used to build the vaccine.

However, people who had been infected with Covid-19 before vaccination retained considerable immunity a finding some scientists say suggests boosters could have a similar effect and shows the variant cannot completely escape antibodies.

Omicron vs Delta: battle of coronavirus mutants is critical

The research “strongly suggests that the Sars-CoV-2 Omicron variant escapes antibody immunity induced by the Pfizer-BioNTech (Comirnaty) vaccine, but that considerable immunity is retained in people who were both vaccinated and previously infected,” said a statement from the Africa Health Research Institute, where Sigal and his co-authors are based.

Antibody levels are considered a rough approximate for protection against Covid-19 infection, but they are not the body’s only form of defence. The latest research did not address how well other arms of the immune system would defend against the variant, or what the impact would be on protection against severe disease.

Africa Health Research Institute executive director Professor Willem Hanekom said the real-world implications of the laboratory data still “need to be determined”.

“It is likely that lesser vaccine-induced protection against infection and disease would be the result. Importantly, most vaccinologists agree that the current vaccines will still protect against severe disease and death in the face of Omicron infection,” he said in a statement on Tuesday.

“The bottom line is that the BioNTech/Pfizer vaccine could still offer some protection,” said virologist Jin Dong-Yan at the University of Hong Kong, pointing as well to local evidence of antibody response in a handful of travellers to Hong Kong who were infected with Omicron.

“The data is still very limited. There are reasons to be optimistic, but it remains to be seen,” Jin said. “We expect that more data will come out in the coming days and weeks and then we can have a much better idea.”

The South African data was based on samples of blood serum taken from 12 vaccinated people that were then exposed to the live Omicron virus. Six participants had no previous record of Covid-19 infection, while the other six had a record of previous infection from South Africa’s first wave with the original strain of the coronavirus.

The previously infected participants had a higher baseline of antibodies, which kept their overall levels higher despite the drop when faced with Omicron.

Immunologist Kylie Quinn, a research fellow with RMIT University in Melbourne, said the finding meant there were still antibodies that were able to recognise the virus, and it was possible that booster shots could help to mitigate the reduction in neutralising activity.

“This data highlights that if a booster dose of current vaccines is available to you ... it’s a great idea to go out and get [that dose],” she said.

Meanwhile, more information was needed for a full picture of the impact on disease severity, according to Quinn.

“I wouldn’t be surprised that there was a drop in protection against infection with Omicron, but the correlation with severe disease is less clear. We could quite possibly see that the vaccine is doing very well against severe disease,” she said.

WHO sounds Omicron warning for unvaccinated vulnerable travellers

Another early study, conducted by Swedish researchers using a different method, found a wide range of reduction of neutralisation against Omicron versus against the early strain of the virus.

That study included people who had antibodies against the original strain, but whose vaccination status was not specified.

Reduction in antibody levels relative to the original strain was “highly variable”, but around seven-fold on average, according to authors from Stockholm’s Karolinska Institutet, who made an early release of their non-peer-reviewed data.

Immunologist Joanna Kirman, who was not involved in the research, said these findings were “less alarming” than the South African results, and suggest that for previously-infected individuals the decrease in neutralisation is not much greater than it is for the Delta variant.

But neither study measured the body’s other forms of immune protection, or could say if the remaining levels of antibodies were enough to reduce disease severity.

That was “the most important thing”, said Kirman, who is an associate professor at New Zealand’s University of Otago.

More data is expected in the coming days and weeks as more information emerges about hospitalisation and severe illness trends in the growing number of Omicron-infected patients globally.

Initial reports have suggested that the disease is not more severe than previous strains. However, scientists warn that there is a time lag before hospitalisation and deaths typically occur.

More from South China Morning Post:

For the latest news from the South China Morning Post download our mobile app. Copyright 2021.

Article type: free
User access status:
Join our Telegram channel to get our Evening Alerts and breaking news highlights

SCMP , Covid-19 , Omicron

   

Next In Aseanplus News

Philippines logs 22,958 new Covid-19 cases
High Saudi death toll overshadows Indonesia's plans to allow ‘umrah’
Dream Cruises to continue operating in Singapore, even as parent company files to be wound up
The hunt for Beijing's wild cats
Laos, Cambodia seek to bolster shared tourism
Cops say illegals on capsized boat near Pontian paid boatman RM580 each and were promised jobs
Proton to introduce smart automobile's new energy vehicles in Asean
Myanmar football teams withdraw from tournaments again
Lee Zii Jia tenders resignation from BAM
TikTok owner ByteDance reorganises strategic investment team

Others Also Read


Vouchers